Logo

American Heart Association

  18
  0


Final ID: MP585

AI-CVD vs. PREVENT for Predicting Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis (MESA)

Abstract Body (Do not enter title and authors here): Background: The AI-CVD initiative aims to extract opportunistic screening information from coronary artery calcium (CAC) scans to maximize cardiovascular disease prediction beyond the traditional risk factors and the Agatston CAC score.
Hypothesis: In 2024, the American Heart Association introduced the PREVENT heart failure (HF) risk score based on age, sex, systolic blood pressure, body mass index, glomerular filtration rate (GFR), diabetes, smoking, and anti-hypertensive medication consumption. We sought to compare PREVENT HF vs. AI-CVD risk scores for predicting HF in the Multi-Ethnic Study of Atherosclerosis (MESA).
Method: AI-CVD platform is a collection of deep learning models targeting various componenets of a CAC scan (see figure 1). We applied AI-CVD to 4,554 CAC scans of asymptomatic MESA participants aged 45–84 years (46.9% male). We used selected AI-CVD outputs included cardiac chamber volumes, thoracic skeletal muscle volume and density, epicardial fat volume, percentage of lung emphysema (<950 HU), and percentage of liver fat (<40 HU). Clinical data comprised demographic and anthropometric characteristics, laboratory results, lifestyle factors, and electrocardiogram parameters. Embedded feature selection methods were applied to identify the most important predictors of HF. The AI-CVD risk score for incident HF was developed using FasterRisk, an interpretable machine learning technique. We then compared the performance of PREVENT HF vs. AI-CVD using the area under the receiver operating curve (AUC) and DeLong’s test for predicting HF.
Results: After a median follow-up of 17.7 (IQR: 13.0-18.5) years, 265 (5.8%) cases were diagnosed with HF. Age, GFR, hypertension, anti-hypertensive medication consumption, smoking, microalbuminuria, diabetes, left atrial volume, ratio of left ventricle to right ventricle volume, left ventricular mass, CAC score, epicardial fat volume, and emphysema were selected features for predicting HF. The AUC for AI-CVD (AUC: 0.84 [95% CI:0.82-0.87]) was significantly (P < 0.001) higher than for PREVENT HF (AUC: 0.77, 95% CI: 0.74-0.81) for 10-year HF prediction.
Conclusion: By integrating AI-generated opportunistic screening biomarkers from CAC scans with clinical data, the AI-CVD risk score significantly outperformed the PREVENT risk score for HF prediction in MESA participants over 10 years.
  • Naghavi, Morteza  ( HeartLung Technologies , Houston , Texas , United States )
  • Mirjalili, Seyed Reza  ( HeartLung Technologies , Houston , Texas , United States )
  • Atlas, Kyle  ( HeartLung Technologies , Houston , Texas , United States )
  • Zhang, Chenyu  ( HeartLung Technologies , Houston , Texas , United States )
  • Reeves, Anthony  ( Cornell University , Ithaca , New York , United States )
  • Azimi, Amir  ( HeartLung Technologies , Houston , Texas , United States )
  • Wong, Nathan  ( University of California, Irvine , Irvine , California , United States )
  • Author Disclosures:
    Morteza Naghavi: DO have relevant financial relationships ; Ownership Interest:HeartLung.AI:Active (exists now) | Seyed Reza Mirjalili: DO have relevant financial relationships ; Researcher:HeartLung:Active (exists now) | Kyle Atlas: No Answer | Chenyu Zhang: DO have relevant financial relationships ; Employee:HeartLung Corporation:Active (exists now) ; Individual Stocks/Stock Options:HeartLung Corporation:Active (exists now) | Anthony Reeves: DO have relevant financial relationships ; Individual Stocks/Stock Options:HeartLung Technologies:Active (exists now) | Amir Azimi: No Answer | Nathan Wong: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen, Novartis, Ionis:Active (exists now) ; Consultant:Ionis:Past (completed) ; Speaker:Novartis:Past (completed) ; Consultant:Heart Lung, Amgen, Novartis:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk, Regeneron:Past (completed)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

From Development to Deployment: Best Practices for Validating AI/ML Models in Healthcare

Saturday, 11/08/2025 , 01:45PM - 02:55PM

Moderated Digital Poster Session

More abstracts on this topic:
A multi-proteomic Risk Score Predicts Adverse Cardiovascular Outcomes in Patients with Angina and Non-obstructive Coronary Artery Disease

Huang Jingwen, Lodhi Rafia, Lodhi Saleha, Eldaidamouni Ahmed, Hritani Wesam, Hasan Muhammet, Haroun Nisreen, Quyyumi Arshed, Mehta Puja, Leon Ana, Ko Yi-an, Yang Huiying, Medina-inojosa Jose, Ahmed Taha, Harris Kristen, Alkhoder Ayman, Al Kasem Mahmoud

A Cardiac Targeting Peptide Linked to miRNA106a Targets and Suppresses Genes Known to Cause Heart Failure: Reversing Heart Failure at the Source

Lu Ming, Deng Claire, Taskintuna Kaan, Ahern Gerard, Yurko Ray, Islam Kazi, Zahid Maliha, Gallicano Ian

More abstracts from these authors:
AI-driven Aortic Valve Calcification Measurement in Coronary Artery Calcium Scan Detects Aortic Stenosis Comparably to Human Experts: An AI-CVD Study within the Framingham Heart Study

Naghavi Morteza, Atlas Kyle, Zhang Chenyu, Reeves Anthony, Atlas Thomas, Wasserthal Jakob, Yankelevitz David, Henschke Claudia, Wong Nathan

Predicting Non-Zero Coronary Artery Calcium Score in Middle-Aged Population: Comparing an Artificial Intelligence-based Model with Existing ASCVD Risk Scores in the Multi-Ethnic Study of Atherosclerosis (MESA)

Mcconnell Mike, Mirjalili Seyed Reza, Atlas Kyle, Zhang Chenyu, Azimi Amir, Reeves Anthony, Wong Nathan, Maron David, Naghavi Morteza

You have to be authorized to contact abstract author. Please, Login
Not Available